1933 Industries Past Earnings Performance
Past criteria checks 0/6
1933 Industries has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings growing at 51% annually. Revenues have been growing at an average rate of 2% per year.
Key information
6.8%
Earnings growth rate
22.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 2.0% |
| Return on equity | n/a |
| Net Margin | -67.8% |
| Next Earnings Update | 02 Jul 2024 |
Recent past performance updates
Recent updates
Further Upside For 1933 Industries Inc. (CSE:TGIF) Shares Could Introduce Price Risks After 33% Bounce
Feb 22
1933 Industries Inc. (CSE:TGIF) Soars 33% But It's A Story Of Risk Vs Reward
Dec 22Is 1933 Industries (CSE:TGIF) Using Too Much Debt?
Aug 111933 Industries Inc.'s (CSE:TGIF) Popularity With Investors Is Under Threat From Overpricing
Jun 17Is 1933 Industries (CSE:TGIF) Weighed On By Its Debt Load?
Apr 10Does 1933 Industries (CSE:TGIF) Have A Healthy Balance Sheet?
Oct 15Is 1933 Industries (CSE:TGIF) Using Debt Sensibly?
Jun 30Does 1933 Industries (CSE:TGIF) Have A Healthy Balance Sheet?
Mar 17Auditors Have Doubts About 1933 Industries (CSE:TGIF)
Dec 02Is 1933 Industries (CSE:TGIF) A Risky Investment?
Oct 21Is 1933 Industries (CSE:TGIF) Using Too Much Debt?
Jul 08Revenue & Expenses Breakdown
How 1933 Industries makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Jan 24 | 19 | -13 | 5 | 0 |
| 31 Oct 23 | 19 | -13 | 5 | 0 |
| 31 Jul 23 | 18 | -13 | 5 | 0 |
| 30 Apr 23 | 16 | -8 | 4 | 0 |
| 31 Jan 23 | 16 | -17 | 5 | 0 |
| 31 Oct 22 | 15 | -18 | 4 | 0 |
| 31 Jul 22 | 13 | -18 | 4 | 0 |
| 30 Apr 22 | 12 | -17 | 4 | 0 |
| 31 Jan 22 | 12 | -4 | 4 | 0 |
| 31 Oct 21 | 12 | -5 | 4 | 0 |
| 31 Jul 21 | 12 | -6 | 6 | 0 |
| 30 Apr 21 | 12 | -9 | 9 | 0 |
| 31 Jan 21 | 11 | -14 | 11 | 0 |
| 31 Oct 20 | 11 | -18 | 15 | 0 |
| 31 Jul 20 | 12 | -19 | 17 | 0 |
| 30 Apr 20 | 15 | -20 | 16 | 0 |
| 31 Jan 20 | 17 | -22 | 16 | 0 |
| 31 Oct 19 | 17 | -19 | 15 | 0 |
| 31 Jul 19 | 18 | -18 | 15 | 0 |
| 30 Apr 19 | 17 | -16 | 15 | 0 |
| 31 Jan 19 | 15 | -10 | 12 | 0 |
| 31 Oct 18 | 15 | -8 | 11 | 0 |
| 31 Jul 18 | 13 | -5 | 9 | 0 |
| 30 Apr 18 | 10 | -4 | 7 | 0 |
| 31 Jan 18 | 6 | -4 | 6 | 0 |
| 31 Oct 17 | 3 | -3 | 4 | 0 |
| 31 Jul 17 | 1 | -3 | 3 | 0 |
| 30 Apr 17 | 0 | -3 | 1 | 0 |
| 31 Jan 17 | 0 | -3 | 1 | 0 |
| 31 Oct 16 | 0 | -4 | 2 | 0 |
| 31 Jul 16 | 0 | -4 | 2 | 0 |
Quality Earnings: TGIF is currently unprofitable.
Growing Profit Margin: TGIF is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TGIF is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare TGIF's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TGIF is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (39.8%).
Return on Equity
High ROE: TGIF's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.